An innovative new test for airway inflammation is set to dramatically change the management of airway diseases like asthma. Unlike current practice that relies primarily on monitoring symptoms and lung function, fractional exhaled nitric oxide (FENO) tests for airway inflammation which is the underlying cause of asthma. As a result, it can direct physicians to the most appropriate treatment plan.
Beyond contributing to diagnostisis, FENO is also useful as a monitoring tool because it can test responsiveness to treatment. It can also be used to monitor disease progression as it rapidly detects even subtle changes after exposure to allergens.
There has long been a need for a straightforward, easily applied and accurate tool to assess airway inflammation. FENO meets this need simply and effectively.